Ibex Medical Analytics, currently on the DigitalHealth.London Accelerator, have announced outstanding outcomes in a clinical validation study for the first and only AI-based solution used by pathologists in routine clinical practice. The study was conducted at the University of Pittsburgh Medical Center (UPMC) and is now reported by The Lancet Digital Health, a top-tier peer-reviewed clinical journal.
Sara Nelson, Programme Director of DigitalHealth.London Accelerator said: “Scientific rigor is fundamentally important to the successful use and implementation of digital health products and services, especially in relation to AI. This publication in The Lancet is ground breaking in the AI pathology field, and we are delighted to do all we can to support Ibex as they continue to be pioneering in cancer AI detection.”
The Lancet publication is the first to report on the performance metrics of an AI solution that is used by pathologists in routine clinical practice.
Tal Frieman of Ibex, commenting on the outstanding performance of their AI-solution in a study at University of Pittsburgh Medical Center (UPMC) as reported in The Lancet said: “Since we joined the DigitalHealth.London Accelerator our business has gone from strength to strength. This publication in The Lancet is hugely exciting for us as it validates the accuracy and clinical utility of our solution in detecting cancer. Through the Accelerator we have access to NHS professionals and experts in the implementation of digital innovations. There is a shortage of pathologists in the UK which impacts service levels of NHS pathology institutes. Now we have this published study, together with the support of the Accelerator, we are in a strong position to drive adoption of AI for pathology into the NHS in London.”
The article in The Lancet Digital Health is available online here.